EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Self- versus clinician-collected swabs in anal cancer screening: A clinical trial

Clare E F Dyer iD, Fengyi Jin, Jennifer M Roberts, I Mary Poynten, Annabelle Farnsworth, Leon P McNally, Philip H Cunningham, Andrew E Grulich, Richard J Hillman

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0312781 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2025. Verfasst von Clare E F Dyer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kirby Institute, University of New South Wales, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Anus Neoplasms, Early Detection of Cancer, Specimen Handling. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Vincent's Clinic Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risk of anal cancer is high in certain populations and screening involves collection of anal swabs for HPV DNA and/or cytology testing. However, barriers exist, such as the need for an intimate examination, and stigma around HIV status, sexual orientation, and sexual practices. Self-collected anal swabs (SCA) are a proposed alternative to clinician-collected swabs (CCA) to overcome these barriers.

Methods

Participants were order-randomised to undergo SCA or CCA first, with a second swab taken immediately afterwards. Sample adequacy was assessed for HPV DNA and cytology testing. CCA was used as the gold standard to calculate sensitivity and specificity of SCA for cytology and HPV results. Acceptability of swab collection was assessed following the procedure.

Results

There was no significant difference in sample validity for HPV DNA testing between SCA and CCA (p = 0.564). Concordance was >90% for detection of any HR-HPV and HPV16. There was no significant difference in cellular adequacy for cytological testing between SCA and CCA, (p = 0.162). Concordance for cytologic prediction was 88.2% for any cytologic abnormality. Almost half (48.5%) of participants expressed no preference for SCA versus CCA; 15.2% preferred SCA and 35.4% CCA.

Conclusions

SCA may be an acceptable and feasible alternative to CCA for detecting HPV and cytological abnormalities in a clinic population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anus NeoplasmsEarly Detection of CancerSpecimen HandlingHumansMaleFemaleMiddle AgedAdultPapillomavirus InfectionsDNA, ViralAgedSensitivity and SpecificityPapillomaviridae

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Douglass Hanly Moir Pathology, Sydney, NSW, Australia.
  • NSW State Reference Laboratory for HIV, St Vincent's Hospital, Sydney, NSW, Australia.
  • St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW, Australia.
  • Dysplasia and Anal Cancer Services, St Vincent's Hospital, Sydney, NSW, Australia.

ORCID-Profile: Clare E F Dyer

Förderung

  • St. Vincent's Clinic Foundation

Zitieren

APA

Dyer, C. E. F., Jin, F., Roberts, J. M., Poynten, I. M., Farnsworth, A., McNally, L. P., Cunningham, P. H., Grulich, A. E., & Hillman, R. J. (2025). Self- versus clinician-collected swabs in anal cancer screening: A clinical trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0312781

Vancouver

Dyer CEF, Jin F, Roberts JM, Poynten IM, Farnsworth A, McNally LP, et al. Self- versus clinician-collected swabs in anal cancer screening: A clinical trial. PLOS ONE. 2025. doi:10.1371/journal.pone.0312781

BibTeX
@article{Dyer2025,
  author = {Dyer, Clare E F and Jin, Fengyi and Roberts, Jennifer M and Poynten, I Mary and Farnsworth, Annabelle and McNally, Leon P and Cunningham, Philip H and Grulich, Andrew E and Hillman, Richard J},
  title = {Self- versus clinician-collected swabs in anal cancer screening: A clinical trial},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0312781}
}
Kostenlos starten →